The Anti-Biofilm Mechanism of Bactorinol®: The Core of Its Clinical Innovation
From Clinic to Laboratory: What We Already Knew About Bactorinol®
The first clinical study, conducted on 100 CRS patients, had already shown remarkable results:
- 67% reduction of bacterial biofilm
- 68% reduction of pathogenic bacteria
- 85% reduction of nasal secretions
- 39% reduction of the impact on the quality of life of patients with chronic rhinosinusitis (SNOT-22)
- improved ciliary motility and cellular integrity
These data established Bactorinol® as an effective therapeutic option capable of improving quality of life and reducing disease severity.
However, they did not yet explain how Winterized Lentisk Oil produced these results — a crucial element for strong clinical and commercial positioning.
From Congo Red to Crystal Violet: A Breakthrough in Mechanism Understanding
While the first clinical study clearly documented Bactorinol®’s benefits, it did not explain how Winterized Lentisk Oil (WLO) produced its anti-biofilm effects.
To answer this question, a new dedicated mechanistic study — recently published in Minerva Medica — set out to investigate the biological basis behind Bactorinol®’s clinical performance.
Earlier in-vitro research had relied on the Congo Red method, which could measure only one aspect: the inhibition of biofilm formation.
However, to fully understand CRS pathology and the potential of WLO, it was essential to determine whether the substance could also act on mature, highly resistant biofilm, the true driver of chronicity and recurrence.
This new study introduced a more advanced approach by adopting the Crystal Violet method, allowing researchers to:
- quantify biofilm production
- evaluate the capacity to degrade already-formed biofilm
This methodological upgrade provided, for the first time, a clear and comprehensive picture of the dual mechanism of action behind Bactorinol®.
Preventing and Breaking Down Biofilm: The Numbers That Matter
The results clearly show that Bactorinol® acts on multiple key CRS pathogens:
Biofilm formation inhibition
- −37% for Moraxella catarrhalis
- −47% for Streptococcus pyogenes
- −56% for Streptococcus pneumoniae
Biofilm degradation
- −30% for catarrhalis
- −60% for pyogenes
These findings provide the first accurate, quantifiable demonstration of Winterized Lentisk Oil’s anti-biofilm activity.
For Business Developers, this means a clear, distinctive, and scientifically grounded value proposition.
Why Biofilm Is the Root of CRS Recurrence
CRS recurrence is driven not only by inflammation but by the persistence of biofilm, which:
- protects pathogenic (harmful) bacteria from antibiotics ⚠
- reduces the effectiveness of nasal irrigation
- allows rapid recolonization by pathogenic bacteria
Because Bactorinol® acts directly on biofilm — the structural “safe haven” of pathogenic bacteria — its in-vitro results align perfectly with the clinical improvements observed in the first study:
- improved SNOT-22
- reduced secretions
- enhanced mucociliary clearance
In short: breaking biofilm means breaking the CRS recurrence cycle.
Regulatory Progress: Advancing Successfully Toward MDR Registration
Bactorinol® (Medical Device) is now available as Nasal drops and Nasal spray to better address different patient needs and age groups, offering tailored solutions for both children and adults. Alongside the growing clinical and in-vitro evidence, Bactorinol® is also progressing successfully through the regulatory pathway required for MDR certification.
This process is approaching completion, positioning Bactorinol® as a product that is not only effective and differentiated, but also on the verge of full regulatory readiness for key markets — a crucial advantage for Business Developers looking to secure long-term, scalable opportunities.
